If you thought AstraZeneca's asset-sale streak was over, think again. The British drugmaker is selling some rights to its acid reflux med Losec—a surprising move, given the continuing uncertainty ...

Acting legally, even within the specific framework of regulatory procedures, is not necessarily a defense to antitrust allegations of abuse of dominance. That’s the clear–and perhaps startling– ...